| 1. |
New epilepsy treatment guidelines that aim to educate physicians about treatment options and provide patients with improved QOL |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 452,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Desloratadine a QOL tonic for chronic idiopathic urticaria, SAR |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 452,
2004,
Page 3-4
&NA;,
Preview
|
|
摘要:
Chronic idiopathic urticaria is a troubling dermatological condition that is defined as the daily, or almost daily, recurrence of urticarial wheals for more than 6 weeks for which no particular infectious, drug-induced or physical cause can be identified. It is characterised by repeated mediator release leading to red, raised, well-demarcated, itchy wheals (or hives), triggered by intolerance to food additives, infections or autoantibodies. Not surprisingly, chronic idiopathic urticaria has a significant negative impact on patients' social and psychological well-being. Avoidance of triggers may prove difficult in chronic idiopathic urticaria, hence, pharmacological treatment is recommended. Antihistamines are the first-line choice of therapy, with newer agents preferred over older ones, due to their nonsedating properties, and superior efficacy. Likewise, seasonal allergic rhinitis (SAR) causes bothersome symptoms which can affect patients' performance at work and school, and lead to poor QOL. Desloratadine is a potent, nonsedating H1-receptor antagonist that has been shown to effectively improve symptoms of chronic idiopathic urticaria and SAR. Two studies presented at a poster session at the 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology [San Francisco, US; March 2004] aimed to assess the symptom and QOL benefits of desloratadine in the treatment of patients with chronic idiopathic urticaria or SAR.
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
The changing face of the US health insurance industry |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 452,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Cost of care in OA, back pain vs matched controls |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 452,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Greater adherence to hypertension guidelines could save > $US1 billion |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 452,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Venlafaxine worthwhile for first-line depression treatment in the UK |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 452,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Potential savings huge from greater use of generics among US elderly |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 452,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Up to 20% of new drug prescriptions never get filled, and 85% of refills never leave the pharmacy, |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 452,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Sildenafil safely improves QOL in men with moderate heart failure? |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 452,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
WHO backs more costly malaria drugs, joins GSK project |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 452,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
